CLINICAL STUDY: HEART FAILURE
Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure
Wendy Johnson, MD*,
Torbjørn Omland, MD*,
Christian Hall, MD ,
Caroline Lucas, MD ,
Ole L. Myking, MD ,
Caroline Collins, RN*,
Marc Pfeffer, MD, FACC*,
Jean-Lucien Rouleau, MD, FACC|| and
Lynne W. Stevenson, MD, FACC*,*
* Brigham and Women’s Hospital, Cardiovascular Division, Harvard Medical School, Boston, Massachusetts, USA
Research Institute for Internal Medicine, University of Oslo, Oslo, Norway
Rijnland Hospital, Leiderdorp, Netherlands
University Hospital of Bergen, Department of Clinical Chemistry, Division of Endocrinology, Bergen, Norway
|| Toronto General Hospital, University of Toronto, Cardiology Division, Toronto, Canada
Manuscript received October 1, 2001;
revised manuscript received February 13, 2002,
accepted February 19, 2002.
* Reprint requests and correspondence: Dr. Lynne W. Stevenson, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115.
OBJECTIVES: This study was designed to determine whether therapy with vasodilators and diuretics, designed to normalize loading conditions in decompensated heart failure (HF), reduces neurohormonal activation in the short term.
BACKGROUND: Elevated vasoactive neurohormone levels in chronic HF have adverse prognostic impact and may be targeted by specific therapies.
METHODS: Endothelin-1, catecholamines, renin, aldosterone, angiotensin and atrial natriuretic peptides (ANP, N-ANP and BNP) were measured in 34 patients with advanced HF before and after hemodynamically guided therapy with vasodilators and diuretics. The therapy was designed to reduce filling pressures and systemic vascular resistance (SVR) without inotropic therapy. Blood was drawn before therapy (A), after initial diuretic and nitroprusside therapy to optimize hemodynamics (B, mean 1.4 days) and after transition to an oral regimen designed to maintain improved hemodynamics (C, mean 3.4 days).
RESULTS: Mean pulmonary wedge pressure fell from 31 to 18 mm Hg, right atrial pressure from 15 to 8 mm Hg, and SVR from 1,780 to 1,109 dynes/s/cm–5. Cardiac index increased from 1.7 to 2.6 l/min/m2 without intravenous inotropic agents (all p  0.05). Average endothelin levels declined by 30%, from 7.7 to 5.5 pg/ml, and remained low at time point C, 5.2 pg/ml (p < 0.01). Norepinephrine was 858 at time A, 817 at time B, and fell by time C to 608 pg/ml (p 0.05). The mean plasma BNP level fell by 26% after only 1.4 days and by 53% at time C (p < 0.001).
CONCLUSIONS: Neurohormonal activation rapidly decreases after short-term therapy tailored to decrease severely elevated filling pressures and SVR without inotropic agents. Therapy designed to address neurohormonal activation should include therapy to improve severe resting hemodynamic compromise.
|
Abbreviations and Acronyms
| | ACE | | angiotensin-converting enzyme | | ANP | | atrial natriuretic peptide | | BNP | | brain natriuretic peptide | | HF | | heart failure | | LV | | left ventricle/ventricular | | N-ANP | | N-terminal fragment of atrial natriuretic peptide prohormone |
|
This article has been cited by other articles:
|
|
|
|
 
M. Metra, S. Nodari, G. Parrinello, C. Specchia, L. Brentana, P. Rocca, F. Fracassi, T. Bordonali, P. Milani, R. Danesi, et al.
The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T
Eur J Heart Fail,
August 1, 2007;
9(8):
776 - 786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Circulation,
July 31, 2007;
116(5):
e99 - e109.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schou, F. Gustafsson, A. Kjaer, and P. R. Hildebrandt
Long-term clinical variation of NT-proBNP in stable chronic heart failure patients
Eur. Heart J.,
January 11, 2007;
(2007)
ehl449v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schou, F. Gustafsson, P. H. Nielsen, L. H. Madsen, A. Kjaer, and P. R. Hildebrandt
Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state
Eur J Heart Fail,
January 1, 2007;
9(1):
68 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Braunschweig, A. Fahrleitner-Pammer, M. Mangiavacchi, S. Ghio, P. Fotuhi, U. C. Hoppe, and C. Linde
Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure
Eur J Heart Fail,
December 1, 2006;
8(8):
797 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kubanek, I. Malek, J. Bytesnik, P. Fridl, L. Riedlbauchova, L. Karasova, V. Lanska, and J. Kautzner
Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months
Eur J Heart Fail,
December 1, 2006;
8(8):
832 - 840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.I. Larsen, K. Dickstein, N.S. Ahmadi, T. Aarsland, J.T. Kvaloy, and C. Hall
The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure
Eur J Heart Fail,
October 1, 2006;
8(6):
628 - 633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Maeder, T. Fehr, H. Rickli, and P. Ammann
Sepsis-Associated Myocardial Dysfunction: Diagnostic and Prognostic Impact of Cardiac Troponins and Natriuretic Peptides
Chest,
May 1, 2006;
129(5):
1349 - 1366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Uemura, A. Kamiya, I. Hidaka, T. Kawada, S. Shimizu, T. Shishido, M. Yoshizawa, M. Sugimachi, and K. Sunagawa
Automated drug delivery system to control systemic arterial pressure, cardiac output, and left heart filling pressure in acute decompensated heart failure
J Appl Physiol,
April 1, 2006;
100(4):
1278 - 1286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Moertl
Response to Letters to the Editor: Short-term effects of levosimendan and prostaglandin E1 on haemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure
Eur J Heart Fail,
March 1, 2006;
8(2):
218 - 218.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D.R. Thackray, K. Witte, J. Ghosh, N. Nikitin, A. Anderson, A. Rigby, K. Goode, A. L. Clark, and J. G.F. Cleland
N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population
Eur. Heart J.,
February 2, 2006;
27(4):
447 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Moertl, R. Berger, M. Huelsmann, A. Bojic, and R. Pacher
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure
Eur J Heart Fail,
December 1, 2005;
7(7):
1156 - 1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Fang
Angiotensin-Converting Enzyme Inhibitors or {beta}-Blockers in Heart Failure: Does It Matter Who Goes First?
Circulation,
October 18, 2005;
112(16):
2380 - 2382.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Shah, V. Hasselblad, L. W. Stevenson, C. Binanay, C. M. O'Connor, G. Sopko, and R. M. Califf
Impact of the Pulmonary Artery Catheter in Critically Ill Patients: Meta-analysis of Randomized Clinical Trials
JAMA,
October 5, 2005;
294(13):
1664 - 1670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Adlam, P. Silcocks, and N. Sparrow
Using BNP to develop a risk score for heart failure in primary care
Eur. Heart J.,
June 1, 2005;
26(11):
1086 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M U Braun, T Rauwolf, T Zerm, M Schulze, A Schnabel, and R H Strasser
Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones
Heart,
May 1, 2005;
91(5):
601 - 605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Nieminen
Pharmacological options for acute heart failure syndromes: current treatments and unmet needs
Eur. Heart J. Suppl.,
April 1, 2005;
7(suppl_B):
B20 - B24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Chockalingam, S. Venkatesan, S. Dorairajan, V. Chockalingam, T. Subramaniam, V. Jaganathan, S. Elangovan, R. Alagesan, G. Gnanavelu, and A. S. Arul
Safety and Efficacy of Enalapril in Multivalvular Heart Disease with Significant Mitral Stenosis--SCOPE-MS
Angiology,
March 1, 2005;
56(2):
151 - 158.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Endorsed by the European Society of Intensive Care, Authors/Task Force Members, M. S. Nieminen, M. Bohm, M. R. Cowie, H. Drexler, G. S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, et al.
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology
Eur. Heart J.,
February 2, 2005;
26(4):
384 - 416.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Albert, C. A. Eastwood, and M. L. Edwards
Evidence-Based Practice for Acute Decompensated Heart Failure
Crit. Care Nurse,
December 1, 2004;
24(6):
14 - 29.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bruins, M. R. Fokkema, J. W.P. Romer, M. J.L. DeJongste, F. P.L. van der Dijs, J. M.W. van den Ouweland, and F. A.J. Muskiet
High Intraindividual Variation of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in Patients with Stable Chronic Heart Failure
Clin. Chem.,
November 1, 2004;
50(11):
2052 - 2058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gackowski, R. Isnard, J.-L. Golmard, F. Pousset, A. Carayon, G. Montalescot, J.-S. Hulot, D. Thomas, W. Piwowarska, and M. Komajda
Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure
Eur. Heart J.,
October 2, 2004;
25(20):
1788 - 1796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schenk, P. M. McCarthy, R. C. Starling, K. J. Hoercher, M. D. Hail, Y. Ootaki, G. S. Francis, K. Doi, J. B. Young, and K. Fukamachi
Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy
J. Thorac. Cardiovasc. Surg.,
July 1, 2004;
128(1):
38 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. de Denus, C. Pharand, and D. R. Williamson
Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone
Chest,
February 1, 2004;
125(2):
652 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Clerico and M. Emdin
Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review
Clin. Chem.,
January 1, 2004;
50(1):
33 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. W. Stevenson
Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward? Part I: Inotropic Infusions During Hospitalization
Circulation,
July 22, 2003;
108(3):
367 - 372.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Futterman and L. Lemberg
Diuretics, The Most Critical Therapy in Heart Failure, Yet Often Neglected in the Literature
Am. J. Crit. Care.,
July 1, 2003;
12(4):
376 - 380.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ruskoaho
Cardiac Hormones as Diagnostic Tools in Heart Failure
Endocr. Rev.,
June 1, 2003;
24(3):
341 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. N. Khot, G. M. Novaro, Z. B. Popovic, R. M. Mills, J. D. Thomas, E. M. Tuzcu, D. Hammer, S. E. Nissen, and G. S. Francis
Nitroprusside in Critically Ill Patients with Left Ventricular Dysfunction and Aortic Stenosis
N. Engl. J. Med.,
May 1, 2003;
348(18):
1756 - 1763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
